AIM2 and non-small cell lung carcinoma: Luteolin-induced G2/M phase arrest and inhibited EMT via the downregulation of AIM2 in NSCLC cells, indicating that AIM2 might be a novel and promising therapeutic target for NSCLC and proposing a potential molecular mechanism of luteolin treatment.